

CLARENCE M. FULBRIGHT.COM
DIRECT DIAL: (512) 536-5674

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

CP 1645
RECEIVED

JUL 10 2002

TECH CENTER 1600/2900

June 26, 2002


**COPY OF PAPERS
ORIGINALLY FILED**

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

June 27, 2002

Date


Charles P. Landrum

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/076,267 entitled "FUSION PROTEINS BASED UPON SOMATOSTATIN RECEPTORS" by Vikas Kundra*
Client Reference: MDA02-038
Our Reference: UTSC:753US


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C1-C2).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10204663/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Charles P. Landrum
Patent Agent
Reg. No. 46,855

CPL/cmb
Encl.: as noted

25181968.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor Application of:
Vikas Kundra

Serial No.: 10/076,267

Filed: February 14, 2002

For: FUSION PROTEINS BASED UPON
SOMATOSTATIN RECEPTORS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSC:753US

RECEIVED

JUL 10 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

June 27, 2002

Date

Charles P. Landrum
Charles P. Landrum

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

**COPY OF PAPERS
ORIGINALLY FILED**

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10204663/SLH.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Charles P. Landrum
Reg. No. 46,855
Agent for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 27, 2002

Form PTO-1449 (modified)

Atty. Docket No.

Serial N .

UTSC:753US

10/076,267

List of Patents and Publications for Applicant

Applicant

Vikas Kundra

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

February 14, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Koller <i>et al.</i> , "A generic method for the production of cell lines expressing high levels of 7-transmembrane receptors," <i>Analytical Biochemistry</i> , 250:51-60, 1997.
	C2	Rogers <i>et al.</i> , "Evaluation of a n adenoviral vector encoding a model chimeric receptor as a receptor for imaging gene transfer," <i>Molecular Therapy</i> , 3(5), S57, Abstract No. 156, 2001.

COPY OF PAPERS
ORIGINALLY FILED

25181903.1

EXAMINER:


DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

JUL 10 2002



TECH CENTER 1600/2900